Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Lantheus Holdings (LNTH)

Lantheus Holdings (LNTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 732,145
  • Shares Outstanding, K 38,820
  • Annual Sales, $ 343,370 K
  • Annual Income, $ 40,520 K
  • 60-Month Beta 1.51
  • Price/Sales 2.14
  • Price/Cash Flow 13.87
  • Price/Book 7.95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 0.25
  • Number of Estimates 1
  • High Estimate 0.25
  • Low Estimate 0.25
  • Prior Year 0.24
  • Growth Rate Est. (year over year) +4.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.85 +4.15%
on 10/08/19
27.12 -31.45%
on 09/24/19
-7.79 (-29.53%)
since 09/20/19
3-Month
17.85 +4.15%
on 10/08/19
29.04 -35.98%
on 07/24/19
-9.67 (-34.22%)
since 07/19/19
52-Week
12.59 +47.66%
on 10/26/18
29.80 -37.62%
on 07/01/19
+5.09 (+37.70%)
since 10/19/18

Most Recent Stories

More News
Lantheus Holdings to Host Third Quarter 2019 Earnings Conference Call on October 31, 2019 at 8:00 a.m. Eastern Time

Lantheus Holdings, Inc. (the "Company") (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, October 31, 2019, to discuss its financial and operating results...

LNTH : 18.59 (-1.43%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, PGNX, DOVA Shareholders About Its Ongoing Investigations

EQNX::TICKER_START (OtherOTC:HLND),(PinkSheets:TNCB),(NASDAQ:PGNX),(NASDAQ:DOVA),(NASDAQ:FCBC),(NASDAQ:RBNC),(NASDAQ:LNTH),(Nasdaq First North Sweden:SOBI), EQNX::TICKER_END

HLND : 8.5200 (+0.71%)
FCBC : 32.62 (+0.93%)
RBNC : 23.89 (+3.24%)
PGNX : 5.06 (+4.33%)
LNTH : 18.59 (-1.43%)
DOVA : 28.32 (+0.89%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection...

PGNX : 5.06 (+4.33%)
LNTH : 18.59 (-1.43%)
PROGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Progenics Pharmaceuticals, Inc. - PGNX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Progenics Pharmaceuticals, Inc. (NasdaqGS: PGNX)...

PGNX : 5.06 (+4.33%)
LNTH : 18.59 (-1.43%)
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Progenics Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Lantheus Holdings, Inc.

Ademi & O'Reilly, LLP is investigating Progenics (Nasdaq: PGNX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Progenics to Lantheus.

LNTH : 18.59 (-1.43%)
PGNX : 5.06 (+4.33%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Progenics Pharmaceuticals, Inc. to Lantheus Holdings, Inc. is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

PGNX : 5.06 (+4.33%)
LNTH : 18.59 (-1.43%)
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on Behalf of Progenics Shareholders and Encourages Progenics Investors to Contact the Firm

Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on behalf of Progenics shareholders concerning the proposed...

LNTH : 18.59 (-1.43%)
PGNX : 5.06 (+4.33%)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Progenics Pharmaceuticals, Inc.

Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the...

PGNX : 5.06 (+4.33%)
LNTH : 18.59 (-1.43%)
Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - PGNX

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) to Lantheus Holdings, Inc. ("Lantheus") for 0.2502 shares of Lantheus...

LNTH : 18.59 (-1.43%)
PGNX : 5.06 (+4.33%)
Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

--Lantheus' Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the Combined Company's Innovative Diagnostic and Radiopharmaceutical Portfolio

LNTH : 18.59 (-1.43%)
PGNX : 5.06 (+4.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Good.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade LNTH with:

Business Summary

Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations,...

See More

Key Turning Points

2nd Resistance Point 19.29
1st Resistance Point 18.94
Last Price 18.59
1st Support Level 18.39
2nd Support Level 18.19

See More

52-Week High 29.80
Fibonacci 61.8% 23.23
Fibonacci 50% 21.19
Fibonacci 38.2% 19.16
Last Price 18.59
52-Week Low 12.59

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar